Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

被引：0
|
作者：
Gaetano Chirico
Roberto Ravasio
Urbano Sbarigia
机构：
[1] Spedali Civili,Neonatologia e Terapia Intensiva Neonatale
[2] Wolters Kluwer Health/Adis International Ltd,Health Economics
[3] Market Access & Health Policies,undefined
来源：
Italian Journal of Pediatrics | / 35卷
关键词：
Preterm Infant; Respiratory Syncytial Virus; Incremental Cost; Incremental Cost Effectiveness Ratio; Respiratory Syncytial Virus Infection;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
    Chirico, Gaetano
    Ravasio, Roberto
    Sbarigia, Urbano
    [J]. ITALIAN JOURNAL OF PEDIATRICS, 2009, 35
  • [2] COST-EFFECTIVENESS ANALYSIS OF PALIVIZUMAB AS A PROPHYLAXIS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN HIGH-RISK LATE PRETERM INFANTS IN THE NETHERLANDS
    Langenfeld, M. K.
    Visser, S.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A372 - A372
  • [3] Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
    Mejias, Asuncion
    Ramilo, Octavio
    [J]. BIOLOGICS-TARGETS & THERAPY, 2008, 2 (03): : 433 - 439
  • [4] Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants
    Vogel, AM
    Lennon, DR
    Broadbent, R
    Byrnes, CA
    Grimwood, K
    Mildenhall, L
    Richardson, V
    Rowley, S
    [J]. JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2002, 38 (06) : 550 - 554
  • [5] Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
    M. Sanchez-Luna
    R. Burgos-Pol
    I. Oyagüez
    J. Figueras-Aloy
    M. Sánchez-Solís
    F. Martinón-Torres
    X. Carbonell-Estrany
    [J]. BMC Infectious Diseases, 17
  • [6] Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
    Sanchez-Luna, M.
    Burgos-Pol, R.
    Oyaguez, I.
    Figueras-Aloy, J.
    Sanchez-Solis, M.
    Martinon-Torres, F.
    Carbonell-Estrany, X.
    [J]. BMC INFECTIOUS DISEASES, 2017, 17
  • [7] COST-EFFECTIVENESS OF PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) WITH PALIVIZUMAB IN PRETERM INFANTS IN COLOMBIA
    Rosselli, D.
    Rueda, J. D.
    Ruiz, J. G.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A75 - A75
  • [8] Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia
    Ordonez, Jaime E.
    Huertas, Victor M.
    [J]. BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [9] Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: A cost-effectiveness analysis
    Lolfand, JH
    Touch, SM
    O'Connor, JP
    Chatterton, ML
    Moxey, ED
    Paddock, LE
    Nash, DB
    Desai, SA
    [J]. CLINICAL THERAPEUTICS, 2000, 22 (11) : 1357 - 1369
  • [10] Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants: A note of caution
    Suresh, S
    Schilling, S
    Dakin, C
    Harris, MA
    [J]. JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2003, 39 (08) : 637 - 637
12345